Published in Proc Natl Acad Sci U S A on May 15, 1991
An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol (1991) 12.00
Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc Natl Acad Sci U S A (1993) 1.62
Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol (1994) 1.30
Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc Natl Acad Sci U S A (1992) 1.20
The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Res (1993) 1.19
Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. Mol Cell Biol (1995) 1.16
Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. Br J Cancer (1993) 1.15
Cloning of mid-G1 serum response genes and identification of a subset regulated by conditional myc expression. Mol Biol Cell (1994) 1.10
The tumor suppressor p53 regulates its own transcription. Mol Cell Biol (1993) 1.08
ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Proc Natl Acad Sci U S A (1996) 1.06
p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol (1993) 0.93
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene (2016) 0.83
p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. Br J Cancer (1993) 0.83
Cyclin E restores p53 activity in contact-inhibited cells. Mol Cell Biol (1995) 0.83
Identification of an upstream region of the mouse p53 promoter critical for transcriptional expression. Nucleic Acids Res (1995) 0.77
DTIE, a novel core promoter element that directs start site selection in TATA-less genes. Nucleic Acids Res (2015) 0.75
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry (1979) 180.95
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell (1989) 21.54
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
Functional inactivation of genes by dominant negative mutations. Nature (1987) 13.12
Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A (1989) 11.76
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
The "initiator" as a transcription control element. Cell (1989) 11.13
The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation. Cell (1990) 7.94
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (1985) 7.07
MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer. Cell (1989) 6.94
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Presence of a potent transcription activating sequence in the p53 protein. Science (1990) 6.38
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature (1985) 5.69
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 5.47
MyoD family: a paradigm for development? Genes Dev (1990) 5.32
Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature (1984) 4.86
Yeast centromere binding protein CBF1, of the helix-loop-helix protein family, is required for chromosome stability and methionine prototrophy. Cell (1990) 4.59
Characterization of the human p53 gene. Mol Cell Biol (1986) 4.33
Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci U S A (1987) 4.21
Six distinct nuclear factors interact with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer. Mol Cell Biol (1987) 4.02
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
The HIV-1 Tat protein: an RNA sequence-specific processivity factor? Cell (1990) 3.28
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A (1990) 3.20
Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A (1985) 3.15
The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell (1989) 3.01
Transcription initiation from the dihydrofolate reductase promoter is positioned by HIP1 binding at the initiation site. Mol Cell Biol (1990) 2.96
Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins. J Biol Chem (1989) 2.89
lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell (1989) 2.84
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U S A (1990) 2.77
Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol (1990) 2.73
p53: oncogene or anti-oncogene? Genes Dev (1990) 2.60
The 5' region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. EMBO J (1985) 2.17
Simian virus 40 major late promoter: a novel tripartite structure that includes intragenic sequences. Mol Cell Biol (1988) 2.09
Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus. Oncogene (1988) 1.96
The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene (1990) 1.75
p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. Oncogene (1990) 1.59
Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles. Mol Cell Biol (1990) 1.58
Mouse p53 blocks SV40 DNA replication in vitro and downregulates T antigen DNA helicase activity. Oncogene (1988) 1.53
Sequences downstream of the transcription initiation site modulate the activity of the murine dihydrofolate reductase promoter. Mol Cell Biol (1990) 1.52
Wild type human p53 is antiproliferative in SV40-transformed hamster cells. Oncogene (1990) 1.47
Biological and molecular analysis of p53 cellular-encoded tumor antigen. Adv Cancer Res (1985) 1.40
A TATA-like sequence located downstream of the transcription initiation site is required for expression of an RNA polymerase II transcribed gene. Genes Dev (1990) 1.37
Protein-binding elements in the promoter region of the mouse p53 gene. Oncogene (1990) 1.27
Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. Proc Natl Acad Sci U S A (1988) 1.27
Characterization of the human p53 gene promoter. Mol Cell Biol (1989) 1.25
A downstream-element-binding factor facilitates assembly of a functional preinitiation complex at the simian virus 40 major late promoter. Mol Cell Biol (1990) 1.21
Two promoters that map to 5'-sequences of the human p53 gene are differentially regulated during terminal differentiation of human myeloid leukemic cells. Oncogene (1989) 0.84
Nuclear factor-1 (NF-1) binds to multiple sites within the transcriptional enhancer of Moloney murine leukemia virus. FEBS Lett (1990) 0.80
A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A (1984) 10.91
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (1985) 7.07
A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol (1985) 6.44
trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol (1986) 6.00
Human p53 gene localized to short arm of chromosome 17. Nature (1986) 4.67
Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature (2000) 3.78
Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50. J Virol (1980) 3.30
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res (2000) 3.30
Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A (1985) 3.15
Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell (1984) 3.05
Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol (1990) 2.73
Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene (1988) 2.71
Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents. J Virol (1981) 2.56
Immunologically distinct p53 molecules generated by alternative splicing. Mol Cell Biol (1986) 2.20
Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol (1986) 2.14
p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proc Natl Acad Sci U S A (1983) 2.03
Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences. Mol Cell Biol (1984) 2.00
Mutant p53 proteins bind DNA abnormally in vitro. Oncogene (1991) 1.96
Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood (1989) 1.85
Nuclear localization is essential for the activity of p53 protein. Oncogene (1991) 1.83
Transcription regulation by mutant p53. Oncogene (2007) 1.78
Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene (1993) 1.77
Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol Cell Biol (1985) 1.72
c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ (1993) 1.72
Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc Natl Acad Sci U S A (1991) 1.65
Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene (1987) 1.52
A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res (1991) 1.49
Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood (1994) 1.47
In vitro expression of human p53 cDNA clones and characterization of the cloned human p53 gene. Mol Cell Biol (1985) 1.46
Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene (1990) 1.45
Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat Med (1998) 1.43
Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther (2010) 1.41
Biological and molecular analysis of p53 cellular-encoded tumor antigen. Adv Cancer Res (1985) 1.40
Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res (1991) 1.40
Expression of p53 in human leukemia and lymphoma. Blood (1986) 1.40
Involvement of p53 in cell differentiation and development. Biochim Biophys Acta (1997) 1.38
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene (2007) 1.35
Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J (2001) 1.32
Regulation of AIF expression by p53. Cell Death Differ (2006) 1.31
Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol (1994) 1.30
Cloning overlapping DNA fragments from the B95-8 strain of Epstein-Barr virus reveals a site of homology to the internal repetition. J Virol (1981) 1.29
Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. Proc Natl Acad Sci U S A (1988) 1.27
Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene (1998) 1.24
Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene (1995) 1.24
Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene (2006) 1.23
Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species. Mol Cell Biol (1984) 1.21
Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ (2010) 1.21
p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol (1998) 1.20
The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Res (1993) 1.19
Variation in antigenic determinants of p53 transformation-related protein obtained from various species. J Immunol (1983) 1.19
Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett (1999) 1.19
A fast signal-induced activation of Poly(ADP-ribose) polymerase: a novel downstream target of phospholipase c. J Cell Biol (2000) 1.16
Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. EMBO J (1995) 1.16
Thymus cell population exerting a regulatory function in the immune response of mice to polyvinyl pyrrolidone. Cell Immunol (1974) 1.15
Chromosomal assignment of the murine gene encoding the transformation-related protein p53. Mol Cell Biol (1984) 1.14
Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. Oncogene (1993) 1.13
Introduction: p53--the first twenty years. Cell Mol Life Sci (1999) 1.12
Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk. Oncogene (2011) 1.12
Effects of varying task constraints on solutions to joint coordination in a sit-to-stand task. Exp Brain Res (2001) 1.10
Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Mol Cell Biol (2001) 1.10
Cancer cells suppress p53 in adjacent fibroblasts. Oncogene (2008) 1.10
Testicular tissue-specific expression of the p53 suppressor gene. Dev Biol (1993) 1.09
PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene (1997) 1.07
Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. Oncogene (2009) 1.06
Transcriptional repression of p53 by human T-cell leukemia virus type I Tax protein. J Biol Chem (1995) 1.06
p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol (1996) 1.06
Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth Differ (1991) 1.05
A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol (1995) 1.04
Direct involvement of p53 in programmed cell death of oligodendrocytes. EMBO J (1995) 1.04
Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene (1993) 1.04
COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Res (1999) 1.03
p53 controls low DNA damage-dependent premeiotic checkpoint and facilitates DNA repair during spermatogenesis. Cell Growth Differ (1999) 1.01
p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53. Oncogene (2000) 1.01
Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J (2001) 1.00
p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death Differ (2012) 0.99
A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells. Genomics (1996) 0.99
Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Differ (1996) 0.99
Increased mitogenic reactivity of normal spleen cells to T lectins induced by thymus humoral factor (THF). Cell Immunol (1975) 0.98
p53 increases experimental metastatic capacity of murine carcinoma cells. Mol Cell Biol (1988) 0.97
Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53. Cancer Epidemiol Biomarkers Prev (1999) 0.97
Restoration of cellular immune response by levamisole in patients with Hodgkin's disease. Biomedicine (1975) 0.97
Lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the gene. Leukemia (2002) 0.96
Modifications of cell cycle controlling nuclear proteins by transforming growth factor beta in the HaCaT keratinocyte cell line. Oncogene (1992) 0.94
Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress. Oncogene (2007) 0.94
p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ (2013) 0.93
Severe disseminated adenovirus infection successfully treated with a thymic humoral factor, THF. Acta Paediatr Scand (1977) 0.93
An EBNA-negative, EBV-genome-positive human lymphoblast cell line in which superinfecting EBV DNA is not maintained. Virology (1984) 0.93
Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. Proc Natl Acad Sci U S A (1995) 0.92
p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. Cancer Res (2001) 0.92
Studies on the effect of a thymic humoral factor on differentiation of thymus-derived lymphocytes. Eur J Immunol (1973) 0.91
Role of wild type p53 in the G2 phase: regulation of the gamma-irradiation-induced delay and DNA repair. Oncogene (1997) 0.91
The presence of p53 transformation-related protein in Ab-MuLV transformed cells is required for their development into lethal tumors in mice. Int J Cancer (1983) 0.90
Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies. J Autoimmun (2001) 0.90
Structural and functional involvement of p53 in BER in vitro and in vivo. Oncogene (2001) 0.90
Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells. Cancer Res (1996) 0.90
p53 is a regulator of macrophage differentiation. Cell Death Differ (2004) 0.90
Resistance to hydrocortisone conferred upon thymocytes by a thymic humoral factor. Eur J Immunol (1974) 0.89
Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy. Oncogene (2011) 0.89